Antagonistic and antibacterial activity of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 included in the oral probiotic
- Authors: Budilovskaya O.V.1,2, Spasibova E.V.1,2, Shalepo K.V.1,2, Khusnutdinova T.A.1,2, Krysanova A.A.1,2, Siniakova A.A.3, Bespalova O.N.1, Savicheva A.M.1,2
-
Affiliations:
- The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
- Saint Petersburg State Pediatric Medical University
- The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott
- Issue: Vol 73, No 3 (2024)
- Pages: 27-39
- Section: Original Research
- Submitted: 23.04.2024
- Accepted: 24.04.2024
- Published: 17.07.2024
- URL: https://journals.eco-vector.com/jowd/article/view/630698
- DOI: https://doi.org/10.17816/JOWD630698
- ID: 630698
Cite item
Abstract
BACKGROUND: A microbial imbalance in the vaginal biotope leads to the development of vaginal infections and is associated with urinary tract infections. The ineffectiveness of the therapy and the frequent recurrence of these infections are important reasons for searching for alternative treatment strategies. A progressive solution to this issue has been the use of oral probiotics with a targeted effect on the intestinal and vaginal microflora.
AIM: The aim of this study was to evaluate the antagonistic and antibacterial activity of the probiotic strains Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14, which are the components of the oral probiotic, against opportunistic microorganisms of intestinal origin, while assessing the sensitivity of these strains to antimicrobial drugs.
MATERIALS AND METHODS: The probiotic strains Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 included in the oral probiotic Duogynal® were cultivated and the grown colonies were identified using the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry method (Bruker Daltonics GmbH & Co., Germany). To study the antagonism of the probiotic strains of lactobacilli and opportunistic pathogenic microorganisms, the following 11 clinical isolates were collected: Escherichia coli (two isolates), Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter asburiae, Proteus mirabilis, Citrobacter freundii, Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, and Candida albicans. To assess the sensitivity of the probiotic strains to antimicrobial drugs, the Gram Positive AST panel (Autobio Diagnostics Co., Ltd, China) was used.
RESULTS: When the microorganisms were co-cultivated with the probiotic lactobacilli (Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14), we noted a decrease in pH and the death of opportunistic microorganisms such as Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter asburiae, Proteus mirabilis, Citrobacter freundii, Staphylococcus aureus, Enterococcus faecalis, and Streptococcus agalactiae, as well as yeast-like fungi Candida albicans. When studying antibiotic resistance, it was found that the both strains of lactobacilli were resistant to ampicillin, vancomycin, daptomycin, clindamycin, linezolid, moxifloxacin, nitrofurantoin, oxacillin, oritavancin, penicillin, rifampin, teicoplanin, tigecycline, trimethoprim/sulfamethoxazole, cefoxitin, ceftarolin, and ciprofloxacin.
CONCLUSIONS: The oral probiotic, which contains a combination of two lactobacilli (Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14), has pronounced antagonistic activity against opportunistic microorganisms. These strains are resistant to most antibacterial drugs used in widespread clinical practice, which may be the basis for recommending the use of this probiotic drug together with prescribed antibiotics for prevention of vaginal or intestinal dysbiosis.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Olga V. Budilovskaya
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Author for correspondence.
Email: o.budilovskaya@gmail.com
ORCID iD: 0000-0001-7673-6274
SPIN-code: 7603-6982
MD, Cand. Sci. (Med.)
Russian Federation, Saint Petersburg; Saint PetersburgElena V. Spasibova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Email: elena.graciosea@gmail.com
ORCID iD: 0009-0002-6070-4651
SPIN-code: 3585-8770
Russian Federation, Saint Petersburg; Saint Petersburg
Kira V. Shalepo
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Email: 2474151@mail.ru
ORCID iD: 0000-0002-3002-3874
SPIN-code: 2527-7198
MD, Cand. Sci. (Med.)
Russian Federation, Saint Petersburg; Saint PetersburgTatiana A. Khusnutdinova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Email: husnutdinovat@yandex.ru
ORCID iD: 0000-0002-2742-2655
SPIN-code: 9533-9754
MD, Cand. Sci. (Med.)
Russian Federation, Saint Petersburg; Saint PetersburgAnna A. Krysanova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Email: krusanova.anna@mail.ru
ORCID iD: 0000-0003-4798-1881
SPIN-code: 2438-0230
MD, Cand. Sci. (Med.)
Russian Federation, Saint Petersburg; Saint PetersburgAnna A. Siniakova
The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott
Email: annakizeeva@yandex.ru
ORCID iD: 0000-0003-3094-665X
SPIN-code: 7795-8364
MD, Cand. Sci. (Med.)
Russian Federation, Saint PetersburgOlesya N. Bespalova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: shiggerra@mail.ru
ORCID iD: 0000-0002-6542-5953
SPIN-code: 4732-8089
MD, Dr. Sci. (Med.)
Russian Federation, Saint PetersburgAlevtina M. Savicheva
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University
Email: savitcheva@mail.ru
ORCID iD: 0000-0003-3870-5930
SPIN-code: 8007-2630
MD, Dr. Sci. (Med.), Professor, Honored Worker of Science of the Russian Federation
Russian Federation, Saint Petersburg; Saint PetersburgReferences
- Döderlein A. Das scheidensekret und seine bedeutung für das puerperalfieber. Leipzig: Besold; 1892. (in Ger.)
- Zheng J, Wittouck S, Salvetti E, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020;70(4):2782–2858. doi: 10.1099/ijsem.0.004107
- Pramanick R, Mayadeo N, Warke H, et al. Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: are they different from normal microbiota? Microb Pathog. 2019;134. doi: 10.1016/j.micpath.2019.103599
- Donders GG, Van Calsteren K, Bellen G, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG. 2009;116(10):1315–1324. doi: 10.1111/j.1471-0528.2009.02237.x
- Stapleton AE. The vaginal microbiota and urinary tract infection. Microbiol Spectr. 2016;4(6). doi: 10.1128/microbiolspec.UTI-0025-2016
- Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol. 2017;35(3):347–354. doi: 10.4103/ijmm.IJMM_16_292
- Asadi Karam MR, Habibi M, Bouzari S. Urinary tract infection: pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Mol Immunol. 2019;108:56–67. doi: 10.1016/j.molimm.2019.02.007
- Kline KA, Lewis AL. Gram-positive uropathogens, polymicrobial urinary tract infection, and the emerging microbiota of the urinary tract. Microbiol Spectr. 2016;4(2). doi: 10.1128/microbiolspec.UTI-0012-2012
- Kirjavainen PV, Pautler S, Baroja ML, et al. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin Vaccine Immunol. 2009;16(1):29–36. doi: 10.1128/CVI.00323-08
- Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42–50. doi: 10.1016/j.maturitas.2016.05.015
- Prevention of early-onset neonatal group B streptococcal disease: green-top Guideline No. 36. BJOG. 2017;124(12):e280–e305. doi: 10.1111/1471-0528.14821
- Khvan VO, Shipitsyna EV, Zatsiorskaya SL, et al. Frequency and risk factors of colonization of pregnant women with group B streptococci. Journal of Obstetrics and Women’s Diseases. 2017;66(6):44–58. EDN: KNJTFE doi: 10.17816/JOWD66644-58
- Money D, Allen VM. The prevention of early-onset neonatal group B streptococcal disease. J Obstet Gynaecol Can. 2013;35(10):939–948. doi: 10.1016/S1701-2163(15)30818-5
- Bradshaw CS, Morton AN, Hocking J., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780
- Arastehfar A, Kargar ML, Mohammadi SR et al. A high rate of recurrent vulvovaginal candidiasis and therapeutic failure of azole derivatives among iranian women. Front Microbiol. 2021;12. doi: 10.3389/fmicb.2021.655069
- Renard J, Ballarini S, Mascarenhas T, et al. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther. 2015;4(1):125–135. doi: 10.1007/s40121-014-0054-6
- Kolousova KA, Shipitsyna EV, Shalepo KV, et al. Virulence and pathogenicity factors of S. agalactiae strains isolated from pregnant women and newborns. Journal of Obstetrics and Women’s Diseases. 2021;70(5):15–22. EDN: OATELN doi: 10.17816/JOWD75671
- Khusnutdinova TA, Shipitsyna EV, Krysanova AA, et al. Profiles and genetic determinants of antimicrobial resistance in pathogens causing community-acquired urinary tract infections in reproductive-age women. Medical alphabet. 2021;(18):12–15. EDN: FXXPWN doi: 10.33667/2078-5631-2021-18-12-15
- Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011;9(4):233–243. doi: 10.1038/nrmicro2536
- Agamennone V, Krul CAM, Rijkers G, et al. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in the Netherlands. BMC Gastroenterol. 2018;18(1):103. doi: 10.1186/s12876-018-0831-x
- Larcombe S, Hutton ML, Lyras D. Involvement of bacteria other than clostridium difficile in antibiotic-associated Diarrhoea. Trends Microbiol. 2016;24(6):463–476. doi: 10.1016/j.tim.2016.02.001
- Shah T, Baloch Z, Shah Z, et al. The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases. Int J Mol Sci. 2021;22(12). doi: 10.3390/ijms22126597
- Sanders ME, Merenstein D, Merrifield CA, et al. Probiotics for human use. Nutrition bulletin. 2018;43(3):212–225. doi: 10.1111/nbu.12334
- Hempe LS, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–1969. doi: 10.1001/jama.2012.3507
- Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis. 2012;205(10):1580–1588. doi: 10.1093/infdis/jis242
- Bastani P, Homayouni A, Tabrizian VG, et al. Dairy probiotic foods and bacterial vaginosis: a review on mechanism of action. In: Rigobelo E, editor. Probiotics. IntechOpen; 2012. doi: 10.5772/50083
- Leonova MV. Probiotics in the treatment of vaginal infections: efficacy from the perspective of evidence-based medicine. Medical Council. 2020;(13):148–154. EDN: COCSOB doi: 10.21518/2079-701X-2020-13-148-154
- Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol. 1999;65(9):3763–3766. doi: 10.1128/AEM.65.9.3763-3766.1999
- Conway PL, Gorbach SL, Goldin BR., et al. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70(1):1–12. doi: 10.3168/jds.S0022-0302(87)79974-3
- Santos CMA, Pires MCV, Leao TL, et al. Selection of Lactobacillus strains as potential probiotics for vaginitis treatment. Microbiology. 2016;162(7):1195–1207. doi: 10.1099/mic.0.000302
- Mogha KV, Prajapati JB. Probiotics for treating bacterial vaginosis. Rev Med Microbiol. 2016;27(3):87–94. doi: 10.1097/MRM.0000000000000080
- Bertuccini L, Russo R, Iosi F, et al. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Int J Immunopathol Pharmacol. 2017;30(2):163–167. doi: 10.1177/0394632017697987
- Russo R, Superti F, Karadja E, et al. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328–335. doi: 10.1111/myc.12883
- De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta(®) complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867. doi: 10.1007/s00404-015-3711-4
- Minkina GN, Bondarenko KR, Selikhova MS, et al. Renaissance of the vaginal microbiota: reframing clinical paradigms. Russian Journal of Woman and Child Health. 2022;5(4):303–308 EDN: PVHVKW doi: 10.32364/2618-8430-2022-5-4-303-308
- ChenYC, LeeWC, ChuangYC. Emerging non-antibiotic options targeting uropathogenic mechanisms for recurrent uncomplicated urinary tract infection. Int J Mol Sci. 2023;24(8):7055. doi: 10.3390/ijms24087055
- Bhatia M, Mitsi V, Court L. The outcomes of pregnancies with reduced fetal movements: A retrospective cohort study. Acta Obstet Gynecol Scand. 2019;98:1450–1454. doi: 10.1111/aogs.13671
- Siniakova AA, Shipitsyna EV, Budilovskaya OV, et al. The efficiency of treatment of vaginal infections in women with a history of miscarriage. Journal of Obstetrics and Women’s Diseases. 2019;68(5):63–74. EDN: YHKWUN doi: 10.17816/JOWD68563-74
- Olsen P, Williamson M, Traynor V et al. The impact of oral probiotics on vaginal group B streptococcal colonisation rates in pregnant women: a pilot randomised control study. Women Birth. 2018;31(1):31–37. doi: 10.1016/j.wombi.2017.06.012
- Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–1330. doi: 10.1097/GME.0000000000001236
- Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol. 2013;36(3):229–238.
- Nader-Macías MEF, De Gregorio PR, Silva JA. Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract. Pharmacol Res Perspect. 2021;9(5). doi: 10.1002/prp2.787
- .Szczerbiec D, Słaba M, Torzewska A. Substances secreted by Lactobacillus spp. from the urinary tract microbiota play a protective role against Proteus mirabilis infections and their complications. Int J Mol Sci. 2023;25(1):103. doi: 10.3390/ijms25010103
- Leccese Terraf MC, Juarez Tomás MS, Rault L, et al. In vitro effect of vaginal lactobacilli on the growth and adhesion abilities of uropathogenic Escherichia coli. Arch Microbiol. 2017;199(5):767–774. doi: 10.1007/s00203-016-1336-z
- Wang C, Fan A, Li H, et al. Vaginal bacterial profiles of aerobic vaginitis: a case-control study. Diagn Microbiol Infect. Dis. 2020;96. doi: 10.1016/j.diagmicrobio.2019.114981
- Zhang Z, Wang X, Li F. An exploration of alginate oligosaccharides modulating intestinal inflammatory networks via gut microbiota. Front Microbiol. 2023;14. doi: 10.3389/fmicb.2023.1072151
- Goodman C, Keating G, Georgousopoulou E, et al. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8). doi: 10.1136/bmjopen-2020-043054
Supplementary files
![](/img/style/loading.gif)